Brand Reference: Loniten
| Metric | Verified Benchmark | Source |
|---|---|---|
| Low-Dose Oral Minoxidil (LDOM 1.25–2.5 mg) RxNorm Concept ID | 6984 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0640 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $8.00 / mo | 47 Zero-PHI Verified Patient Logs |
Converted by hepatic sulfotransferase SULT1A1 (bypassing variable scalp follicular SULT1A1 deficiency that causes 40% topical non-response) into active minoxidil sulfate, opening vascular KATP channels, upregulating dermal papilla VEGF/Wnt-beta-catenin, and prolonging follicular anagen.
Out-of-pocket price dispersion on Low-Dose Oral Minoxidil (LDOM 1.25–2.5 mg) spans $5.80 to $34.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.0640/unit, allowing cash buyers bypassing PBM spread pricing to retain $28.20 each month (83% reduction).
With 3–4.2 hours plasma / 24-hour follicular KATP effect residence kinetics and 90% oral bioavailability, Low-Dose Oral Minoxidil (LDOM 1.25–2.5 mg) undergoes 90% hepatic sult1a1 sulfation and glucuronidation; renal clearance and establishes therapeutic activity over 4–8 weeks telogen shed release; 16–24 weeks terminal hair caliber jump.
Standard adult regimens span 0.625 mg PO QHS (women start), 1.25 mg PO QHS, 2.5 mg PO once daily, 2.5 mg PO BID (men refractory). Prescribers screen specifically against pericarditis or pericardial effusion; unstable angina or severe congestive heart failure; pheochromocytoma, while community micro-logs most frequently note transient dread-shed weeks 3–6 (29% of reports), facial/eyebrow vellus hypertrichosis (24% of reports), mild ankle puffiness (5% of reports).
Across 47 verified cash-pay logs, Low-Dose Oral Minoxidil (LDOM 1.25–2.5 mg) achieves a 92.80% Worth-It rating with out-of-pocket spend averaging $8.00/mo versus $34.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.625 mg PO QHS (women start) for Low-Dose Oral Minoxidil (LDOM 1.25–2.5 mg); monthly out-of-pocket dropped to $5.10 compared with $34.00 retail.
Completed 10 weeks on Low-Dose Oral Minoxidil (LDOM 1.25–2.5 mg) (1.25 mg PO QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 2.5 mg PO once daily Low-Dose Oral Minoxidil (LDOM 1.25–2.5 mg) sourced via Compounding ($6.73/mo cash pay without insurance prior authorization).